TYCC
DFTX

Texas Yale Capital Corp’s Definium Therapeutics DFTX Stock Holding History

Texas Yale Capital Corp’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,153
Closed -$40K – 474
2021
Q3 		$40K Hold
1,153
– – ﹤0.01% 461
2021
Q2 		$60K Buy
+1,153
New +$60.5K ﹤0.01% 465

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Texas Yale Capital Corp's DFTX Position: Q4 2021 in Review

Texas Yale Capital Corp sold out of Definium Therapeutics (DFTX) in Q4 2021, closing a stake of 1,153 shares — an estimated $40K sold.

Texas Yale Capital Corp first reported a position in DFTX in Q2 2021 and held it in 2 quarters. The position peaked at $60K in Q2 2021. 176 funds tracked by Wall St. Rank hold DFTX as of Q4 2021.

  • Texas Yale Capital Corp reported no remaining Definium Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Texas Yale Capital Corp sold 1,153 Definium Therapeutics shares in Q4 2021, an estimated $40K.
  • Texas Yale Capital Corp first reported a position in Definium Therapeutics in Q2 2021 and held it in 2 quarters.
  • Texas Yale Capital Corp's Definium Therapeutics position peaked at $60K in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2021.

Based on Texas Yale Capital Corp's 13F filing for Q4 2021, filed 10 Feb 2022.